Leaflet: information for the user
Tiorfan Lactantes 10 mg powder for oral suspension
racecadotrilo
Read this leaflet carefully before starting to take the medicine.
1. What Tiorfan is and for what it is used
2. What you need to know before starting to take Tiorfan
3. How to take Tiorfan
4. Possible adverse effects
5. Storage of Tiorfan
6. Contents of the pack and additional information
Tiorfan is a medication for the treatment of diarrhea.
Tiorfan is used in the treatment of the symptoms of acute diarrhea in children over 3 months old. It should be used along with an abundant intake of liquid and usual dietary measures, when these measures alone are insufficient to control the diarrhea, and when the causes of the diarrhea cannot be treated.
If possible, the causal treatment, racecadotrilo may be administered as a complementary treatment.
No use Tiorfan
-If your child is allergic to racecadotrilo or any of the other components of Tiorfan (listed in section 6).
-If your doctor has told you that your child has an intolerance to some sugars, ask your doctor before giving Tiorfan to your child.
- If your child has ever developed a severe skin rash or peeling of the skin, blisters, and/or mouth sores after taking racecadotrilo
Warnings and precautions
Consult your doctor or pharmacist before starting togive Tiorfan to your child if:
-Your child is less than 3 months,
-There is blood or pus in your child's stool and if they have a fever. The cause of your child's diarrhea may be a bacterial infection that must be treated by your doctor,
-Your child suffers from chronic diarrhea or diarrhea caused by antibiotics,
-Your child suffers from prolonged or uncontrolled vomiting,
-Your child has a kidney disease or insufficient liver function,
-Your child has diabetes (see “Important information about some of the components of Tiorfan”).
The racecadotril, the active ingredient of Tiorfan, may cause an allergic reaction called angioedema, which can cause swelling of the face, lips, throat, or tongue. If your child experiences these adverse effects, stop the treatment immediately and contact your doctor. The swelling can appear at any time during treatment with this product.
The concomitant use of this product and some other medications may increase the risk of angioedema (see "Other medications and Tiorfan").
Severe skin reactions have been reported with the use of this product. In most cases, they are mild and do not require treatment. In some cases, severe skin reactions may occur. In these cases, treatment should be stopped immediately and the child should not be treated with racecadotril again.
Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), associated with racecadotrilo treatment have been reported. Suspend the use of racecadotrilo and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.
Use of Tiorfan with other medications
Inform your doctor if your child is using, has used recently, or may need to use any other medication.
Especially inform your doctor if your child is using any of the following medications:
Pregnancy and lactation
Tiorfan is not recommended for use during pregnancy and lactation.
Consult your doctor or pharmacist before using this medication.
Driving and operating machinery
Tiorfan has little or no effect, or no effect, on the ability to drive or operate machinery.
Tiorfan contains saccharose
Tiorfan contains approximately 1 g of saccharose per sachet.
If your doctor has told you that your child has an intolerance to some sugars, ask your doctor before giving Tiorfan to your child.
In babies with diabetes, if your doctor has prescribed more than 5 sachets of Tiorfan per day (which corresponds to more than 5 g of saccharose), it should be taken into account in the total daily sugar intake of the child.
Follow exactly the administration instructions for Tiorfan as indicated by your doctor. If in doubt, consult your doctor or pharmacist again.
Tiorfan is presented in granulated form.
The granules can be added to food or mixed in a glass of water or in the baby bottle. Mix well and give it to your child immediately.
The recommended daily dose depends on your child's weight: 1.5 mg/kg per dose (corresponding to 1-2 sachets), three times a day at regular intervals.
In children weighing up to9 kg:one sachet per dose.
In children weighing9 to 13 kg:two sachets per dose.
Your doctor will indicate the duration of treatment with Tiorfan.The treatment must be continued until two normal bowel movements occur, not exceeding 7 days.
To compensate for the fluid loss due to your child's diarrhea, this medication should be used in conjunction with adequate fluid and electrolyte replacement (rehydration). The best rehydration is achieved with an oral rehydration solution (please ask your doctor or pharmacist if unsure).
If you give your child more Tiorfan than you should
If your child has taken more Tiorfan than they should, contact your doctor or pharmacist immediately.
If you forget to give Tiorfan
Do not give your child a double dose to compensate for a missed dose.Simply continue with the treatment.
Stop administering Tiorfan to your child and contact a doctor immediately if your child experiences symptoms of angioedema, such as:
Suspend use of racecadotrilo and seek medical attention immediately if you notice any of the following symptoms:
The following adverse effects have been described:
Rare (may affect up to 1 in 100 people):
Tonsillitis (inflammation of the tonsils), eruption, and erythema (redness of the skin).
Unknown frequency (frequency cannot be estimated from available data):
erythema multiforme (red lesions on the extremities and interior of the mouth), tongue swelling, face swelling, lip swelling, eyelid swelling, urticaria, erythema nodosum (inflammation in the form of lumps under the skin), papular eruption (skin eruption with small, hard, and swollen lesions), prurigo (skin lesions with itching), and pruritus (generalized itching).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use (www.notificaram.es). By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keepthis medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and on the box after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Tiorfan
The active substance is racecadotrilo.Cada sobre contiene 10 mg of racecadotrilo.
The other components are:
sacarosa,
silica colloidal anhydrous,
polycarboxylate dispersion at 30 percent,
orange blossom aroma.
Appearance of Tiorfan and contents of the packaging
Tiorfan is presented in the formgranulated for oral suspension in blisters.
Cada envase contains 10, 16, 20, 30, 50 or 100 blisters (100 blisterssólo comoenvase clínico).
It may only be marketed some sizes of packaging.
Marketing Authorization Holder
BIOPROJET-FERRER, S.L.
Gran Vía Carlos III, 94
08028 Barcelona (Spain)
Responsible for manufacturing
FERRER INTERNACIONAL, S.A.
Joan Buscallà 1-9
08173 Sant Cugat del Vallès, Barcelona (Spain)
or
SOPHARTEX,
21 rue de Pressoir,
28500 Vernouillet (France)
This medicine is authorized in the member states of the European Economic Area with the following names:
GERMANY: Tiorfan
PORTUGAL: Tiorfan
GREECE:Hidrasec
ITALY: Tiorfix
AUSTRIA : Hidrasec
BELGIUM : Tiorfast
CZECH REPUBLIC : Hidrasec
DENMARK : Hidrasec
ESTONIA : Hidrasec
FINLAND : Hidrasec
HUNGARY : Hidrasec
IRELAND : Hidrasec
LATVIA : Hidrasec
LITHUANIA : Hidrasec
LUXEMBOURG : Tiorfast
NETHERLANDS :Tiorfan
POLAND : Hidrasec
SLOVAK REPUBLIC : Hidrasec
SLOVENIA : Hidrasec
SWEDEN : Hidrasec
UNITED KINGDOM : Hidrasec
Last review date of this leaflet: 24-11-2024
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) www.aemps.gob.es.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.